Table 3.
A list of few vaccines that completed clinical trial phase 3
| Vaccine name | Research name | Vaccine type | Manufacturer | Country of origin | Side effects | Efficacy | References |
|---|---|---|---|---|---|---|---|
| Comirnaty | BNT162b2 | 3 LNP-mRNAs | Pfizer, BioNTech, Fosun Pharma | Multinational | Fatigue, headache, myalgia, chills, arthralgia | 95% | Jeff Craven (2021), Kashte et al. (2021) |
| Moderna COVID-19 vaccine | Mrna-1273 | LNP-encapsulated mRNA | Moderna, BARDA, NIAID | US | Tiredness, headache, muscle pain, chills, fever, nausea | 94% | Jeff Craven (2021), Kashte et al. (2021) |
| AstraZeneca also known as Vaxzevria and Covishield | AZD1222 | Non-replicating viral vector ChAdOx1-S | BARDA, OWS | UK | Tiredness, headache, muscle pain, chills, fever, nausea | 70% | Kashte et al. (2021), Jeff Craven (2021) |
| Sputnik V | Non-replicating viral vector | Gamaleya research institute, Acellena contract drug research and development | Russia | Breathing difficulties, convulsions, swelling muscle weakness, high BP, headaches, dizziness | 92% | Kashte et al. (2021), Jeff Craven (2021) | |
| Janssen | JNJ-78436735; Ad26.COV2.S | Non-replicating viral vector | Janssen vaccines (Johnson & Johnson) | The Netherlands, US | Headache, fever, fatigue, muscle aches, nausea, irritation, redness | 68% | Kashte et al. (2021), Jeff Craven (2021) |
| CoronaVac | Inactivated vaccine (formalin with alum adjuvant) | Sinovac | China | Rash, headache, muscle pain, fever, nausea, vomiting, injection site pain, fatigue | 78% | Kashte et al. (2021), Jeff Craven (2021) | |
| Sinopharm | BBIBP-CorV | Inactivated vaccine | Beijing institute of biological products; China national pharmaceutical group (Sinopharm) | China | Lethargy, drowsiness, difficulty sleeping, sneezing, nasopharyngitis, nasal congestion | 86% | Kashte et al. (2021), Jeff Craven (2021) |
| EpiVacCorona | Peptide vaccine | Federal budgetary research institution state research center of virology and biotechnology | Russia | – | – | Jeff Craven (2021) | |
| Convidicea | Ad5-nCoV | Recombinant vaccine (adenovirus type 5 vector) | CanSino Biologics | China | Fever, pain, swelling, sensitivity, fatigue, pain in muscles, joints and heads | 66% | Kashte et al. (2021), Jeff Craven (2021) |
| Covaxin | BBV152 | Inactivated vaccine | Bharat Biotech, ICMR; Ocugen | India | Pain, headache, fatigue, fever, body ache, abdominal pain, nausea, tremor, sweating, cold, cough | 78% | Kashte et al. (2021), Jeff Craven (2021) |
| WIBP-CorV | Inactivated vaccine | Wuhan institute of biological products; China national pharmaceutical group (Sinopharm) | China | Rash, headache, muscle pain, fever, nausea, vomiting, injection site pain | 72,51% | Jeff Craven (2021) | |
| CoviVac | Inactivated vaccine | Chumakov Federal scientific center for research and development of immune and biological products | Russia | – | – | Jeff Craven (2021) | |
| ZF2001 | Recombinant vaccine | Anhui Zhifei Longcom biopharmaceutical institute of microbiology of the Chinese academy of sciences | China, Uzbekistan | Injection pain, redness, swelling | - | Jeff Craven (2021) | |
| QazVac (QazCovid-in) | Inactivated vaccine | Research institute for biological safety problems | Kazakhstan | – | – | Jeff Craven (2021) | |
| Novavax | NVX-Cov2373 | Recombinant nanoparticle | Biofabri in Spain, FUJIFILM Diosynth Biotechnologies (FDB) in both North Carolina and Texas in the US, FDB in the UK, SIIPL in India, SK Bioscience in the Republic of Korea, Takeda Pharmaceutical Company Limited in Japan | UK & South Africa | Rash, headache, muscle pain, fever, nausea, vomiting, injection site pain | 89.3% | Novavax (2021) |